Key Points
- Director Yong Ben sold 2,000 Corbus Pharmaceuticals shares at an average price of $7.84, receiving $15,680 and reducing his direct stake by 17.57% to 9,383 shares.
- Corbus reported positive Phase 1b CANYON-1 results for oral obesity drug CRB-913, including approximately 5% average weight loss after 12 weeks at the 60 mg dose, with no plateau observed and generally favorable tolerability.
- CRBP opened at $6.92, near its 52-week low of $6.32, after the company reported a quarterly EPS loss of $1.81 versus the expected $1.26 loss. Analysts remain broadly positive, with a consensus “Moderate Buy” rating and a $41 average price target.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) Director Yong Ben sold 2,000 shares of the business's stock in a transaction on Monday, September 14th. The shares were sold at an average price of $7.84, for a total transaction of $15,680.00. Following the completion of the sale, the director directly owned 9,383 shares in the company, valued at $73,562.72. This trade represents a 17.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Corbus Pharmaceuticals Stock Performance
Shares of CRBP stock opened at $6.92 on Wednesday. The firm has a fifty day moving average of $9.70 and a 200-day moving average of $9.44. The stock has a market cap of $129.20 million, a price-to-earnings ratio of -1.12 and a beta of 2.63. Corbus Pharmaceuticals Holdings, Inc. has a 52-week low of $6.32 and a 52-week high of $20.56.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.55). On average, sell-side analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post -5.62 earnings per share for the current year.
Key Headlines Impacting Corbus Pharmaceuticals
Here are the key news stories impacting Corbus Pharmaceuticals this week:
- Positive Sentiment: Corbus reported positive topline results from the CANYON-1 Phase 1b trial of oral CRB-913 in obesity. The 60 mg dose produced statistically significant, clinically meaningful average weight loss of 5% after 12 weeks, with no plateau observed. The drug was generally well tolerated, with psychiatric adverse events broadly comparable to GLP-1 medicines and an emerging favorable gastrointestinal tolerability profile. Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study
- Positive Sentiment: The data support CRB-913’s potential as an oral, non-incretin obesity treatment, and the company plans a late-breaking presentation at ObesityWeek 2026. The results prompted HC Wainwright to reaffirm its “buy” rating and maintain a $35 price target, implying substantial upside from recent levels. Corbus Pharmaceuticals Obesity Drug Avoids Depressive Effects
- Neutral Sentiment: Trading in CRBP options was unusually active, with call purchases approximately 523% above typical volume on Monday. This may indicate speculative interest following the trial announcement, but it does not establish the direction of the stock.
- Negative Sentiment: Put-option purchases surged approximately 690% above average on Tuesday, signaling increased bearish hedging or speculation and potentially contributing to short-term selling pressure.
- Negative Sentiment: Director Yong Ben sold 2,000 shares for approximately $15,680, reducing his position by 17.57%. While the transaction is relatively small, insider selling can weigh on investor sentiment.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on CRBP shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research note on Friday, July 17th. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday. Mizuho set a $33.00 price target on Corbus Pharmaceuticals in a research report on Thursday, August 13th. Wedbush dropped their price objective on Corbus Pharmaceuticals from $38.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, May 27th. Finally, Guggenheim reiterated a "buy" rating on shares of Corbus Pharmaceuticals in a research report on Tuesday, May 26th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Corbus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $41.00.
Read Our Latest Analysis on CRBP
Institutional Trading of Corbus Pharmaceuticals
Several large investors have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in shares of Corbus Pharmaceuticals by 53,592.3% in the first quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company's stock valued at $131,000 after buying an additional 13,934 shares in the last quarter. Pale Fire Capital SE lifted its position in Corbus Pharmaceuticals by 14.5% during the 1st quarter. Pale Fire Capital SE now owns 21,350 shares of the biopharmaceutical company's stock worth $200,000 after buying an additional 2,700 shares in the last quarter. Engineers Gate Manager LP grew its holdings in Corbus Pharmaceuticals by 109.9% during the 2nd quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company's stock worth $280,000 after acquiring an additional 15,600 shares during the last quarter. Royal Bank of Canada grew its holdings in Corbus Pharmaceuticals by 81.2% during the 1st quarter. Royal Bank of Canada now owns 29,901 shares of the biopharmaceutical company's stock worth $281,000 after acquiring an additional 13,401 shares during the last quarter. Finally, BRC Group Holdings Inc. acquired a new stake in Corbus Pharmaceuticals in the 4th quarter valued at about $315,000. Institutional investors own 64.64% of the company's stock.
Corbus Pharmaceuticals Company Profile
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company's research programs are designed to target biological pathways involved in tumor growth, immune regulation and tissue fibrosis.
Corbus's oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, a protein expressed on several solid tumors. The company is also developing CRB-601, an investigational monoclonal antibody directed at the alpha v beta 6 integrin, a target associated with tumor biology and fibrotic disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
